NCT01158157View on ClinicalTrials.gov

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 13, 2010

Primary Completion Date

February 14, 2012

Study Completion Date

February 14, 2012

Conditions
Smallpox Vaccine Adverse Reaction
Interventions
BIOLOGICAL

ACAM2000

Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.

Trial Locations (1)

32701

Cangene Plasma Resources, Mid-Florida, Altamonte Springs

Sponsors
All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emergent BioSolutions

INDUSTRY